| abstract |
The present invention relates to a bispecific single chain antibody comprising a first binding domain immunospecifically binding to the T-cell antigen CD3 and a second binding domain immunospecifically binding to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term "EphA2-BiTE". The invention also relates to methods and compositions designed for the treatment, prevention and / or management of disorders associated with abnormal expression and / or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention also relates to vectors comprising polynucleotides encoding EphA2-BiTE of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTE. The present invention also provides a composition comprising a pharmaceutical composition comprising any of the aforementioned EphA2-BiTE, polynucleotides or vectors, alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are kits comprising a screening method for EphA2-BiTE and any of the above-mentioned compositions and diagnostic reagents. |